|
Characteristic
|
No. of patients (%)
|
|---|
|
Agea (years)
|
56 (36–77)
|
|
Sex
|
|
Men
|
18 (66.7)
|
|
Women
|
9 (33.3)
|
|
ISS stageb
|
|
I
|
6 (23.1)
|
|
II
|
14 (53.8)
|
|
III
|
6 (23.1)
|
|
Time since diagnosisa (months)
|
21 (4–60)
|
|
Subtype of disease
|
|
IgG
|
11 (40.7)
|
|
IgA
|
6 (22.2)
|
|
IgD
|
5 (18.5)
|
|
Light chain
|
5 (18.5)
|
|
β2-microglobulinb
|
|
Levela (mg/L)
|
3.4 (1.1–16.7)
|
|
<3.5 mg/L
|
14 (53.8)
|
|
≥3.5 mg/L
|
12 (46.2)
|
|
Prior therapy
|
|
Numbera (cycles)
|
3 (1–8)
|
|
0–3 cycles
|
14 (51.9)
|
|
>3 cycles
|
13 (48.1)
|
|
Prior regimen
|
|
Glucocorticoids
|
25 (92.6)
|
|
Alkylating agents
|
23 (85.2)
|
|
IMiDs (thalidomide or lenalidomide)
|
21 (77.8)
|
|
Vincristine
|
19 (70.3)
|
|
Bortezomib
|
14 (51.9)
|
|
Both bortezomib and IMiDs
|
9 (33.3)
|
|
Autologous stem cell transplantation
|
5 (18.5)
|
-
ISS international staging system, IMiDs immunomodulatory drugs
-
aThese values are presented as median followed by ranges in the parentheses; other values are presented as number of patients followed by percentages in the parentheses
-
bBaseline β2-microglobulin was not determined in one patient; who could not be grouped into any ISS stage
